Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference